“…Evidence for targeting extracellular GrB has been validated via models of various cardiovascular, dermatological, neuroinflammatory, gastroenterological and respiratory pathologies utilizing genetic knockouts, biologics and/or small molecules (Aneurysm - ( Chamberlain et al, 2010 ; Ang et al, 2011 ); Atherosclerosis - (Paul R. Hiebert PR. et al, 2013 ); Cardiac fibrosis - ( Shen et al, 2016 ); Cerebral ischemia - ( Aslam and Yuan, 2020 ); Vascular leakage -( Hendel and Granville, 2013 ; Hendel et al, 2014 ); Chronic wound healing - (P. R. Hiebert P. R. et al, 2013 ; Hsu et al, 2014 ; Turner et al, 2021a ); Skin aging - ( Hiebert et al, 2011 ; Parkinson et al, 2015 ); Scarring - ( Shen et al, 2018 ); Autoimmune blistering - ( Russo et al, 2018 ; Hiroyasu et al, 2021 ); Dermatitis - ( Turner et al, 2021 ); Multiple sclerosis - ( Haile et al, 2015 ); Crohn’s disease - ( Hu et al, 2022 ); Asthma - ( Qian et al, 2020 )). From these studies, pharmacological inhibition of extracellular GrB appears to be the most viable avenue of therapy, with the biologic Serpina3n and the small molecule VTI-1002 both exhibiting therapeutic efficacy.…”